Pazopanib is a potent and selective multi-targeted tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (Flk-1), platelet-derived growth factor receptor (PDGFR) and c-kit, which are key proteins responsible for tumor growth and angiogenesis.